Sign in
NVAX Stock Price, Chart, Stats & News
Novavax, Inc.
Save
1.46B
Market cap
178.00x
Current P/E
2.58x
Forward P/E
NVAX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.32% |
Operating margin | 41.32% |
Pretax margin | 39.36% |
Net margin | 39.19% |
Effective tax rate | 0.42% |
ROA | 37.42% |
ROE | -546.21% |
D/E | -1.95x |
Interest coverage ratio | 20.59x |
NVAX valuation
P/E | 178.00x |
P/S | 1.23x |
P/B | -10.71x |
P/CF | -5.60x |
P/FCF | -5.49x |
P/OCF | -5.60x |
PEG | 0.11x |
EV multiple | 2.78x |
About
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.
Similar securities
Based on sector and market capitalization
Report issue